27.71
+0.20
+(0.75%)
As of 8:02:02 AM GMT+1. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
264,790.00
233,662.00
2,785.00
6,689.00
152.00
Cost of Revenue
30,941.00
14,131.00
265.00
790.00
--
Gross Profit
233,849.00
219,531.00
2,520.00
5,899.00
152.00
Operating Expense
234,354.00
198,898.00
195,359.00
350,669.00
273,746.00
Operating Income
-505.00
20,633.00
-192,839.00
-344,770.00
-273,594.00
Net Non Operating Interest Income Expense
-19,398.00
-12,615.00
-10,191.00
-5,638.00
-6,329.00
Other Income Expense
6,018.00
5,044.00
4,695.00
2,307.00
542.00
Pretax Income
-13,885.00
13,062.00
-198,335.00
-348,101.00
-279,381.00
Tax Provision
479.00
390.00
--
--
--
Net Income Common Stockholders
-14,364.00
12,672.00
-198,335.00
-348,101.00
-279,381.00
Diluted NI Available to Com Stockholders
-14,364.00
12,672.00
-198,335.00
-348,101.00
-279,381.00
Basic EPS
-0.10
0.09
-1.46
-2.63
-2.42
Diluted EPS
-0.10
0.09
-1.46
-2.63
-2.42
Basic Average Shares
144,783.03
141,955.11
135,411.26
132,222.75
115,333.69
Diluted Average Shares
159,318.98
148,508.47
135,411.26
132,222.75
115,333.69
Total Operating Income as Reported
-505.00
20,633.00
-192,839.00
-344,770.00
-273,594.00
Total Expenses
265,295.00
213,029.00
195,624.00
351,459.00
273,746.00
Net Income from Continuing & Discontinued Operation
-14,364.00
12,672.00
-198,335.00
-348,101.00
-279,381.00
Normalized Income
-14,364.00
12,672.00
-198,335.00
-348,101.00
-279,381.00
Interest Expense
19,398.00
12,615.00
10,191.00
5,638.00
6,329.00
Net Interest Income
-19,398.00
-12,615.00
-10,191.00
-5,638.00
-6,329.00
EBIT
5,513.00
25,677.00
-188,144.00
-342,463.00
-273,052.00
EBITDA
5,822.00
26,100.00
-187,629.00
-341,969.00
-272,678.00
Reconciled Cost of Revenue
30,941.00
14,131.00
265.00
790.00
--
Reconciled Depreciation
309.00
423.00
515.00
494.00
374.00
Net Income from Continuing Operation Net Minority Interest
-14,364.00
12,672.00
-198,335.00
-348,101.00
-279,381.00
Normalized EBITDA
5,822.00
26,100.00
-187,629.00
-341,969.00
-272,678.00
Tax Rate for Calcs
0.00
0.00
--
--
--
12/31/2020 - 1/21/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
LTI.SG Aptose Biosciences Inc
0.1950
-6.25%
ANL Adlai Nortye Ltd.
1.9800
0.00%
NVV1.F Novavax, Inc.
8.40
-5.48%
ACRV Acrivon Therapeutics, Inc.
5.34
-2.38%
KTTA Pasithea Therapeutics Corp.
2.6100
-0.38%
IDYA IDEAYA Biosciences, Inc.
22.62
-5.87%
XOMA XOMA Royalty Corporation
24.30
-3.49%
AVTX Avalo Therapeutics, Inc.
6.77
-3.36%
IMMX Immix Biopharma, Inc.
2.0800
-0.95%
HRMY Harmony Biosciences Holdings, Inc.
35.85
+5.86%